1. Home
  2. LUCY vs ERNA Comparison

LUCY vs ERNA Comparison

Compare LUCY & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Eyewear Inc.

LUCY

Innovative Eyewear Inc.

HOLD

Current Price

$0.91

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

BUY

Current Price

$7.89

Market Cap

5.8M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
LUCY
ERNA
Founded
2017
2018
Country
United States
United States
Employees
13
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7M
5.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LUCY
ERNA
Price
$0.91
$7.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
70.0K
1.6M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.29
EPS
N/A
N/A
Revenue
N/A
$582,000.00
Revenue This Year
$175.92
N/A
Revenue Next Year
$205.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.13
52 Week High
$2.90
$15.88

Technical Indicators

Market Signals
Indicator
LUCY
ERNA
Relative Strength Index (RSI) 34.59 48.88
Support Level $0.90 $0.61
Resistance Level $1.07 $15.88
Average True Range (ATR) 0.04 1.35
MACD -0.01 -0.79
Stochastic Oscillator 7.45 4.55

Price Performance

Historical Comparison
LUCY
ERNA

About LUCY Innovative Eyewear Inc.

Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: